sdx-7320
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02743637)
Timeline
Indications
Mechanism of action
- Methionine aminopeptidase 2INHIBITOR
METAP2 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802217 ↗
Also known as
- sdx-7320
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05570253 | Phase 2 | Oct 3, 2022 | Memorial Sloan-Kettering Cancer Center, SynDevRx, Inc. |
| NCT05455619 | Phase 1/Phase 2 (Phase 2) | Aug 26, 2022 | SynDevRx, Inc. |
| NCT02743637 | Phase 1 | Feb 1, 2016 | SynDevRx, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SynDevRx, Inc. | For profit | 3 | 2 | 2 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1